Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-16-2026-01_58_09-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026
  • Policy / Pricing

Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026

KFF Medicare

The Medicare Part D program provides an outpatient prescription drug benefit to 56 million older adults and people with long-term disabilities in Medicare who enroll in private plans.

Read full story

pharminent June 11, 2026 (Last updated: June 19, 2026)

KFF Medicare

The Medicare Part D program provides an outpatient prescription drug benefit to 56 million older adults and people with long-term disabilities in Medicare who enroll in private plans.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs
Next: How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market

Related Stories

  • Policy / Pricing

German said to be backtracking on pharma rebate changes

pharminent June 16, 2026
  • Policy / Pricing

How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market

pharminent June 11, 2026
  • Policy / Pricing

The next FDA commissioner must be a champion for gene therapies

pharminent June 5, 2026

You May Have Missed

  • News

pharminent June 19, 2026
wp_daily_digest_2026-06-19
  • News

pharminent June 19, 2026
  • M&A / Deals

Biogen to acquire RayThera for up to $1bn

pharminent June 19, 2026
  • News

pharminent June 18, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.